Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral tablet for oral use. It works by inhibiting lymphocyte proliferation and is primarily prescribed to prevent organ transplant rejection in adult patients, helping maintain graft function and reduce the risk of acute rejection episodes.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and specialty pharmacies worldwide, providing reliable sourcing, regulatory support, and consistent product quality for transplant programmes through established distribution networks.

Myfortic is an immunosuppressant used in organ transplantation to reduce immune‑mediated graft damage.

Kidney transplantation: helps prevent acute rejection and supports long‑term graft function. Heart transplantation: reduces incidence of rejection episodes and aids graft survival. Liver transplantation: contributes to maintenance of graft function and lowers rejection risk. Pancreas transplantation: forms part of the immunosuppressive regimen to avoid graft loss.

Myfortic may cause a range of adverse reactions. Monitoring and reporting are essential.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Headache: occasional tension‑type pain. - Abdominal pain: cramping or discomfort. - Vomiting: occasional episodes. - Infections: increased susceptibility to common infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Severe infection: opportunistic or systemic infections. - Malignancy: increased risk of certain cancers. - Liver dysfunction: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy: rare brain infection. - Bone marrow suppression: anemia or thrombocytopenia.

Before initiating Myfortic, several safety considerations should be addressed.

Monitor blood counts: perform regular CBC to detect leukopenia. Assess renal function: adjust therapy if renal impairment is present. Avoid live vaccines: immunosuppression may reduce vaccine efficacy. Pregnancy: discuss potential risks with a healthcare provider. Concomitant nephrotoxic drugs: use with caution to avoid kidney injury. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Myfortic can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Cyclosporine: increased risk of nephrotoxicity. - Tacrolimus: may raise mycophenolic acid concentrations. - Antacids containing aluminum or magnesium: reduce drug absorption.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Rifampin: may lower mycophenolic acid levels. - Warfarin: potential alteration of INR and bleeding risk.